XML 83 R74.htm IDEA: XBRL DOCUMENT
v3.22.1

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Aug. 31, 2021 | Jul. 31, 2021 | Dec. 31, 2019 | Apr. 30, 2017 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021
Klarity License Agreement [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Milestone payment in cash |  |  |  |  | $ 30,000 | $ 35,000 |
Royalty expense |  |  |  |  | 71,000 | 35,000 |
Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Royalty payment description |  |  |  | Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of net sales, dependent upon the final formulation of the Klarity Product sold |  |  |
Injectable Asset Purchase Agreement [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Milestone payment in cash |  |  |  |  | 8,000 | 7,000 |
Royalty expense |  |  |  |  | $ 7,000 | 7,000 |
Injectable Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Royalty payment description |  |  | the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold |  |  |  |
Initial milestone payment |  |  | $ 33,000 |  |  |  |
Dexycu Agreement [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Commission expiration date |  |  |  |  | Aug. 01, 2025 |  |
Commission revenues |  |  |  |  | $ 1,320,000 | 485,000 |
Sales and Marketing Agreements [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Description for commission payments |  |  |  |  | Under the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to 10% - 14% of net sales for products above and beyond the initial existing sales amounts |  |
Commission expenses |  |  |  |  | $ 1,047,000,000 | 804,000,000 |
Sales and Marketing Agreements [Member] | Minimum [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Commission payments percentage |  |  |  |  | 10.00% |  |
Sales and Marketing Agreements [Member] | Maximum [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Commission payments percentage |  |  |  |  | 14.00% |  |
Asset Purchase, License and Related Agreements [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Royalty expense |  |  |  |  | $ 213,000 | 232,000 |
Sintetica Agreement [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payment for royalties |  | $ 18,000,000 |  |  |  |  |
Sintetica Agreement [Member] | Research and Development Expense [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payment for royalties |  |  |  |  |  |  | $ 3,117,000
Sintetica Agreement [Member] | Due Within Thirty Days [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payment for royalties |  | $ 5,000,000 |  |  |  |  |
Wakamoto Agreement [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payment for royalties | $ 2,000,000 |  |  |  |  |  |
Commercial payments for royalties | $ 6,200,000 |  |  |  |  |  |
Presbyopia Asset Purchase Agreement [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Milestone payment in cash |  |  |  |  | 0 | 0 |
Royalty expense |  |  |  |  | 0 | 0 |
Milestone payments on payables |  |  |  |  | $ 0 | $ 0 |
Presbyopia Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member] |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Royalty payment description |  |  | the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold |  |  |  |

X
- Definition Commercial payments for royalties. + References No definition available. + Details
Name: | HROW_CommercialPaymentsForRoyalties
Namespace Prefix: | HROW_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commission expiration date. + References No definition available. + Details
Name: | HROW_CommissionExpirationDate
Namespace Prefix: | HROW_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commission payments, percentage. + References No definition available. + Details
Name: | HROW_CommissionPaymentsPercentage
Namespace Prefix: | HROW_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commission revenues + References No definition available. + Details
Name: | HROW_CommissionRevenues
Namespace Prefix: | HROW_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description for commission payments. + References No definition available. + Details
Name: | HROW_DescriptionForCommissionPayments
Namespace Prefix: | HROW_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial milestone payment. + References No definition available. + Details
Name: | HROW_InitialMilestonePayment
Namespace Prefix: | HROW_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment in cash. + References No definition available. + Details
Name: | HROW_MilestonePaymentInCash
Namespace Prefix: | HROW_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payments on payables. + References No definition available. + Details
Name: | HROW_MilestonePaymentsOnPayables
Namespace Prefix: | HROW_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalty payment description. + References No definition available. + Details
Name: | HROW_RoyaltyPaymentDescription
Namespace Prefix: | HROW_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_SalesCommissionsAndFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=HROW_KlarityLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=HROW_RichardLLindstromMDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=HROW_DexycuAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=HROW_AssetPurchaseLicenseAndRelatedAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=HROW_SinteticaAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=HROW_DueWithinThirtyDaysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=HROW_WakamotoAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=HROW_PresbyopiaAssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |